作者: Claudia Hurtado , Gonzalo Encina , Ana María Wielandt , Alejandro José Zárate , Magdalena Castro
DOI: 10.4067/S0034-98872014001100007
关键词: Real-time polymerase chain reaction 、 Pathology 、 Biology 、 Epidermal growth factor receptor 、 Mutation 、 Monoclonal antibody therapy 、 Colorectal cancer 、 Internal medicine 、 Oncology 、 Gene mutation 、 Prospective cohort study 、 KRAS
摘要: Background: The molecular testing of KRAS mutation status in metastatic colorectal cancer patients is mandatory to identify eligible for anti- epidermal growth factor receptor monoclonal antibody therapy. Aim: To report the frequency gene mutations Chilean with (CRC). Material and Methods: A cohort 262 CRC aged 26 90 years (53% males), was studied. analyzed by real-time polymerase chain reaction correlated clinicopathological data. Results: Ninety-eight (37%) were positive mutations. G12D most common a 36.7%, followed G12V (25.5%), G13D (17.3%), G12A (7.1%), G12C (6.1%), G12S (5.1%) G12R (2%). left, right colon rectal tumors 37.8, 32.6 44.9%, respectively. Among mutations, 86.7% well or moderately differentiated rest poorly differentiated. No significant associations between other features tumor observed. Conclusions: frequencies reported this study are similar European North-American populations, lower than Spanish higher Peruvian study. (Rev Med Chile 2014; 142: 1407-1414)